Virtual Incision Announces Publication of Data from its U.S. Investigational Device Exemption Study in the Clinical Journal, Diseases of Colon and Rectum

Data demonstrate the safety and efficacy of the MIRA Surgical System, a novel miniaturized robotic-assisted surgery device, in adults undergoing colectomy procedures

LINCOLN, Neb.–(BUSINESS WIRE)–Virtual Incision Corporation, the developer of the MIRA™ Surgical System (MIRA), today announced data from its Investigational Device Exemption (IDE) clinical study has been published in Diseases of Colon and Rectum. The study was designed to assess the safety and efficacy of MIRA, the world’s first miniaturized robotic-assisted surgery device, in adults undergoing colectomy procedures. Results were provided to the Food and Drug Administration (FDA) as part of the submission to support the de novo marketing authorization of the device.


The data demonstrated the following results:

The primary efficacy endpoint, the successful completion of pre-defined procedural steps without conversion to open surgery, was met.

The primary safety endpoints, overall intraoperative and postoperative adverse events (AEs), and the incidence of serious AEs (device and procedure-related) were also met. There were no intraoperative surgical complications.

“There is a growing body of clinical evidence that suggests short-term outcomes, complications, and quality of life are all improved following a minimally invasive approach for colon surgery,” said John H. Marks, MD, FACS, FASCRS, director of the Colorectal Center at Lankenau Medical Center, chief of the section of colorectal surgery at Main Line Healthcare, and an investigator for the study. “Utilization of robotic-assisted surgery for colectomy procedures is growing and these results suggest that miniaturized robotic-assisted surgery devices can be successfully used in these complex procedures. We’re excited to continue to build upon data supporting the use of miniRAS and look forward to learning more about the potential positive impact on patient and health economic outcomes.”

“The publication of the IDE study data in Diseases of Colon and Rectum marks a key milestone for MIRA as an evidence-based option for surgeons seeking safe and effective outcomes for patients following colectomies,” said Piet Hinoul, MD, PhD, chief medical officer of Virtual Incision. “We look forward to further assessing this miniRAS device for a wide range of procedures and are eager to bring the benefits of robotic-assisted surgery to more patients across the globe.”

About Virtual Incision

Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over two hundred patents and patent applications, the company developed MIRA, the first-of-its-kind miniature RAS system. Virtual Incision’s goal is to make every operating room RAS-ready. For more information, visit our website or follow us on LinkedIn and X.

About the MIRA Surgical System

MIRA is the world’s first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek form factor is designed to offer the benefits of RAS during colectomy procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds (less than one kg) and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room – a dedicated mainframe room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a mainframe. With MIRA, every operating room is RAS-ready.

Important Safety Information

The MIRA Surgical System is intended for prescription use only. Patients should talk to their doctor to decide if surgery with a MIRA Surgical System is right for them. For important safety information, indications for use, risks, and warnings, please refer to www.virtualincision.com/safety-information.

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions.

Contacts

Jenna Kane

Health+Commerce

[email protected]
(480) 388-9587

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.